Therefore, in metabolic disorders, the activity of PON1 and anti-inflammatory and anti-atherosclerotic properties of serum HDL-PON1 complex are significantly decreased due to inactive oxidation and glycation of both free PON1 and HDL-PON1. The gene discussed is PON1; the disease is metabolic disease.